| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/15/2023 | 15.91% | Goldman Sachs | $3.5 → $9.25 | Upgrades | Sell → Neutral |
| 06/22/2023 | 87.97% | JMP Securities | → $15 | Reiterates | Market Outperform → Market Outperform |
| 06/16/2023 | 113.03% | Wells Fargo | → $17 | Initiates Coverage On | → Overweight |
| 06/16/2023 | 25.31% | JP Morgan | $3.3 → $10 | Upgrades | Underweight → Overweight |
| 01/03/2023 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 11/18/2022 | 87.97% | JMP Securities | $32 → $15 | Maintains | Market Outperform |
| 01/14/2022 | — | Morgan Stanley | Downgrades | Overweight → Equal-Weight | |
| 08/06/2021 | — | Deutsche Bank | Downgrades | Buy → Hold | |
| 06/11/2021 | 200.75% | JP Morgan | $32 → $24 | Downgrades | Overweight → Neutral |
| 06/03/2021 | — | Bryan Garnier | Downgrades | Buy → Neutral | |
| 06/03/2021 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 05/24/2021 | 250.88% | Morgan Stanley | → $28 | Upgrades | Equal-Weight → Overweight |
| 03/23/2021 | — | SVB Leerink | Downgrades | Outperform → Market Perform | |
| 11/25/2020 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight | |
| 11/20/2019 | — | Guggenheim | Initiates Coverage On | → Buy | |
| 11/14/2018 | 326.07% | JP Morgan | $32 → $34 | Maintains | Overweight |
| 11/05/2018 | 376.19% | Piper Sandler | → $38 | Initiates Coverage On | → Overweight |
What is the target price for MorphoSys (MOR)?
The latest price target for MorphoSys (NASDAQ: MOR) was reported by Goldman Sachs on September 15, 2023. The analyst firm set a price target for $9.25 expecting MOR to rise to within 12 months (a possible 15.91% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for MorphoSys (MOR)?
The latest analyst rating for MorphoSys (NASDAQ: MOR) was provided by Goldman Sachs, and MorphoSys upgraded their neutral rating.
When is the next analyst rating going to be posted or updated for MorphoSys (MOR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MorphoSys, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MorphoSys was filed on September 15, 2023 so you should expect the next rating to be made available sometime around September 15, 2024.
Is the Analyst Rating MorphoSys (MOR) correct?
While ratings are subjective and will change, the latest MorphoSys (MOR) rating was a upgraded with a price target of $3.50 to $9.25. The current price MorphoSys (MOR) is trading at is $7.98, which is within the analyst's predicted range.